Key result
Modifying sialylation of the soluble glycoprotein angiopoietin-like 4 or changing key amino acids in its sequence shows potential as a therapeutic strategy to treat proteinuria in nephrotic syndrome.
Design
Review
Authors
Loading...
Angptl4 modification remains investigational for proteinuria; leaves open the need for clinical validation in nephrotic syndrome.
This review highlights the central role of Angptl4 in the pathogenesis of nephrotic syndrome components and its potential as a therapeutic target for proteinuria.
Macé et al. (2014) conducted a review in Nephrotic Syndrome. Angiopoietin-Like 4 (Angptl4) targeted therapeutics was evaluated. Modifying sialylation of the soluble glycoprotein angiopoietin-like 4 or changing key amino acids in its sequence shows potential as a therapeutic strategy to treat proteinuria in nephrotic syndrome.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: